Terms: = Lung cancer AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Prognosis
44 results:
1. Humoral complementomics - exploration of noninvasive complement biomarkers as predictors of renal cancer progression.
Revel M; Rezola Artero M; Hamidi H; Grunenwald A; Blasco L; Vano YA; Marie Oudard S; Sanchez-Salas R; Macek P; Rodriguez Sanchez L; Cathelineau X; Vedié B; Sautes-Fridman C; Herman Fridman W; Roumenina LT; Dragon-Durey MA
Oncoimmunology; 2024; 13(1):2328433. PubMed ID: 38487624
[TBL] [Abstract] [Full Text] [Related]
2. Antiproliferative activities of some selected Nigerian medicinal plants against breast, liver, and cervical cancer cells.
Olaleye OO; Kim DH; Spriggs KA
BMC Complement Med Ther; 2024 Mar; 24(1):110. PubMed ID: 38448883
[TBL] [Abstract] [Full Text] [Related]
3. Celastrol impairs tumor growth by modulating the CIP2A-GSK3β-mcl-1 axis in gastric cancer cells.
Wu J; Ye F; Xu T
Aging (Albany NY); 2023 Jul; 15(14):6894-6904. PubMed ID: 37470692
[TBL] [Abstract] [Full Text] [Related]
4. Myeloid cell leukemia-1 as a candidate prognostic biomarker in cancers: a systematic review and meta-analysis.
Wang J; He Y; Yang C; Luo Q; Wang B
Expert Rev Anticancer Ther; 2023; 23(9):1017-1027. PubMed ID: 37467344
[TBL] [Abstract] [Full Text] [Related]
5. Identifies KCTD5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity.
Shi YX; Yan JH; Liu W; Deng J
BMC Cancer; 2023 May; 23(1):408. PubMed ID: 37149576
[TBL] [Abstract] [Full Text] [Related]
6. Gene network Analysis Defines a Subgroup of Small Cell lung cancer patients With Short Survival.
Cucchiara F; Petrini I; Passaro A; Attili I; Crucitta S; Pardini E; de Marinis F; Danesi R; Del Re M
Clin Lung Cancer; 2022 Sep; 23(6):510-521. PubMed ID: 35739016
[TBL] [Abstract] [Full Text] [Related]
7. CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage.
Soleimani A; Navarro A; Liu D; Herman SEM; Chuang SS; Slavutsky I; Narbaitz M; Safah H; Schmieg J; Lefante J; Roschewski M; Wilson WH; Wiestner A; Saba NS
Leuk Lymphoma; 2022 Apr; 63(4):911-917. PubMed ID: 34781807
[TBL] [Abstract] [Full Text] [Related]
8. Transcriptional inhibition by CDK7/9 inhibitor SNS-032 suppresses tumor growth and metastasis in esophageal squamous cell carcinoma.
Zeng H; Yang H; Song Y; Fang D; Chen L; Zhao Z; Wang C; Xie S
Cell Death Dis; 2021 Nov; 12(11):1048. PubMed ID: 34741018
[TBL] [Abstract] [Full Text] [Related]
9. Pan-cancer Analysis Reveals FH as a Potential Prognostic and Immunological Biomarker in lung Adenocarcinoma.
Zhang H; Ju Q; Ji J; Zhao Y
Dis Markers; 2021; 2021():8554844. PubMed ID: 34737838
[TBL] [Abstract] [Full Text] [Related]
10. The Pro-Survival Oct4/Stat1/mcl-1 Axis Is Associated with Poor prognosis in lung Adenocarcinoma Patients.
Su YC; Chen YC; Tseng YL; Shieh GS; Wu P; Shiau AL; Wu CL
Cells; 2021 Oct; 10(10):. PubMed ID: 34685622
[TBL] [Abstract] [Full Text] [Related]
11. Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade.
Daugan MV; Revel M; Thouenon R; Dragon-Durey MA; Robe-Rybkine T; Torset C; Merle NS; Noé R; Verkarre V; Oudard SM; Mejean A; Validire P; Cathelineau X; Sanchez-Salas R; Pickering MC; Cremer I; Mansuet-Lupo A; Alifano M; Sautès-Fridman C; Damotte D; Fridman WH; Roumenina LT
Cancer Immunol Res; 2021 Aug; 9(8):909-925. PubMed ID: 34039652
[TBL] [Abstract] [Full Text] [Related]
12. Overexpression of HSP10 correlates with HSP60 and mcl-1 levels and predicts poor prognosis in non-small cell lung cancer patients.
Tang Y; Yang Y; Luo J; Liu S; Zhan Y; Zang H; Zheng H; Zhang Y; Feng J; Fan S; Wen Q
Cancer Biomark; 2021; 30(1):85-94. PubMed ID: 32986659
[TBL] [Abstract] [Full Text] [Related]
13. NCAPH is negatively associated with mcl‑1 in non‑small cell lung cancer.
Xiong Q; Fan S; Duan L; Liu B; Jiang X; Chen X; Xiong C; Tao Q; Wang J; Zhang H; Chen C; Duan Y
Mol Med Rep; 2020 Oct; 22(4):2916-2924. PubMed ID: 32945371
[TBL] [Abstract] [Full Text] [Related]
14. Ancestry-specific predisposing germline variants in cancer.
Oak N; Cherniack AD; Mashl RJ; ; Hirsch FR; Ding L; Beroukhim R; Gümüş ZH; Plon SE; Huang KL
Genome Med; 2020 May; 12(1):51. PubMed ID: 32471518
[TBL] [Abstract] [Full Text] [Related]
15. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Elstrom R; Huang J; Novotny W; Wei R; Zhu J
Clin Cancer Res; 2020 Aug; 26(16):4216-4224. PubMed ID: 32461234
[TBL] [Abstract] [Full Text] [Related]
16. Overexpression of Antiapoptotic mcl-1 Predicts Worse Overall Survival of Patients With Non-small Cell lung cancer.
Nakano T; Go T; Nakashima N; Liu D; Yokomise H
Anticancer Res; 2020 Feb; 40(2):1007-1014. PubMed ID: 32014946
[TBL] [Abstract] [Full Text] [Related]
17. Elevated expression of mcl-1 inhibits apoptosis and predicts poor prognosis in patients with surgically resected non-small cell lung cancer.
Wen Q; Zhan Y; Zheng H; Zang H; Luo J; Zhang Y; Wang W; Feng J; Lu J; Chen L; Fan S
Diagn Pathol; 2019 Oct; 14(1):108. PubMed ID: 31601252
[TBL] [Abstract] [Full Text] [Related]
18. The clinical impact of family history of cancer in female never-smoker lung adenocarcinoma.
Lee Y; Jeon JH; Goh SH; Roh H; Yun JY; Kwon NJ; Choi JH; Yang HC; Kim MS; Lee JM; Lee GK; Han JY
Lung Cancer; 2019 Oct; 136():15-22. PubMed ID: 31421257
[TBL] [Abstract] [Full Text] [Related]
19. [Research progress in the role of FBXW7 in drug resistance against non-small cell lung cancer].
Peng Z; Chen Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Apr; 44(4):444-448. PubMed ID: 31113922
[TBL] [Abstract] [Full Text] [Related]
20. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
[No Abstract] [Full Text] [Related]
[Next]
